glp-1 market forecast Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Market Size, Share |

doi:10.1016/j.regpep.2014.04.003 140

GLP-1/GIP dual agonists are thought to be more effective at lowering blood glucose and body weight than GLP-1s alone

The drug was approved based on research showing that 63 percent of people who took semaglutide cleared their MASH within 72 weeks compared to 34 percent of people taking a placebo

When compared against previous best-selling drugs of all-time (Keytruda, Humira, Lipitor), GLP-1s look to be on a record-shattering revenue ramp trajectory5

However, patients may experience minor side effects, such as injection site reactions (redness, swelling, or itching) or gastrointestinal symptoms (nausea, vomiting, or diarrhea)

Fundamental Research Funds for Central Universities 2019XZZX001-01-06 (YZ.)